Lakewood-Amedex Biotherapeutics, Inc. (LABT) vs NEXGEL, Inc. (NXGL)
A side-by-side comparison of Lakewood-Amedex Biotherapeutics, Inc. and NEXGEL, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LABT
Lakewood-Amedex Biotherapeutics, Inc.
$0.86HealthcareDelayed quote: Oct 6, 2026, 1:46 PM EDT
NXGL
NEXGEL, Inc.
$0.17HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
Total return — LABT vs NXGL
growth of $100 · dividends reinvested · last 1yLABT -99.0% (-99.0%/yr)NXGL -72.2% (-72.2%/yr)NXGL compounded faster over this window
Log scale — wide-divergence pair
LABT NXGL
LABT vs NXGL: by the numbers
- •LABT is the larger company ($1M vs $1M market cap).
- •Both run net losses; LABT's is the smaller (0.00% vs -51.26% net margin).
Metrics side by side
Valuation
| Metric | LABT | NXGL |
|---|---|---|
| P/S ratio | N/A | 0.12 |
| P/B ratio | 0.35 | 0.29 |
Profitability
| Metric | LABT | NXGL |
|---|---|---|
| Gross margin | 0.00% | 35.07% |
| Operating margin | 0.00% | -29.35% |
| Net margin | 0.00% | -51.26% |
| ROE | -169.64% | -124.97% |
| ROIC | -163.98% | -41.80% |
Growth (annualized)
| Metric | LABT | NXGL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 63.69% |
Go deeper
Dig into the metrics
Lakewood-Amedex Biotherapeutics ROENEXGEL ROELakewood-Amedex Biotherapeutics operating marginNEXGEL operating marginLakewood-Amedex Biotherapeutics revenue growthNEXGEL revenue growthLakewood-Amedex Biotherapeutics free cash flowNEXGEL free cash flow
Lakewood-Amedex Biotherapeutics & NEXGEL appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.